BG103727A - Hiv protease inhibitors - Google Patents
Hiv protease inhibitorsInfo
- Publication number
- BG103727A BG103727A BG103727A BG10372799A BG103727A BG 103727 A BG103727 A BG 103727A BG 103727 A BG103727 A BG 103727A BG 10372799 A BG10372799 A BG 10372799A BG 103727 A BG103727 A BG 103727A
- Authority
- BG
- Bulgaria
- Prior art keywords
- hiv protease
- protease inhibitors
- hiv
- hiv virus
- replication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
HIV protease inhibitors are obtained by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. The compounds, as well as the pharmaceutical compositions that contain them, and optionally other anti-viral agents as active ingredients are suitable for treating patients or hosts infected with the HIV virus which is known to cause AIDS. 37 claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81595197A | 1997-03-13 | 1997-03-13 | |
| PCT/US1998/004735 WO1998040357A2 (en) | 1997-03-13 | 1998-03-12 | Hiv protease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG103727A true BG103727A (en) | 2000-04-28 |
| BG63540B1 BG63540B1 (en) | 2002-04-30 |
Family
ID=25219265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG103727A BG63540B1 (en) | 1997-03-13 | 1999-09-13 | Hiv protease inhibitors |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP0970055A2 (en) |
| JP (1) | JP2001516350A (en) |
| KR (1) | KR100511089B1 (en) |
| CN (1) | CN1179948C (en) |
| AP (1) | AP1358A (en) |
| AR (1) | AR012556A1 (en) |
| AU (1) | AU743078B2 (en) |
| BG (1) | BG63540B1 (en) |
| BR (1) | BR9808867A (en) |
| CA (1) | CA2284163A1 (en) |
| CO (1) | CO4940496A1 (en) |
| CZ (1) | CZ296647B6 (en) |
| EA (1) | EA002378B1 (en) |
| EE (1) | EE04114B1 (en) |
| GE (1) | GEP20022764B (en) |
| HR (1) | HRP980112A2 (en) |
| HU (1) | HUP0001380A3 (en) |
| IL (2) | IL131870A0 (en) |
| IS (1) | IS5176A (en) |
| MX (1) | MXPA99008395A (en) |
| MY (1) | MY117535A (en) |
| NO (1) | NO315555B1 (en) |
| NZ (1) | NZ337706A (en) |
| OA (1) | OA11196A (en) |
| PA (1) | PA8448801A1 (en) |
| PE (1) | PE58799A1 (en) |
| PL (1) | PL192786B1 (en) |
| SA (1) | SA98181116B1 (en) |
| SK (1) | SK283636B6 (en) |
| SV (1) | SV1998000038A (en) |
| TR (1) | TR199902508T2 (en) |
| TW (1) | TW200517112A (en) |
| UA (1) | UA57772C2 (en) |
| WO (1) | WO1998040357A2 (en) |
| ZA (1) | ZA982047B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
-
1998
- 1998-03-04 HR HR08/815,951A patent/HRP980112A2/en not_active Application Discontinuation
- 1998-03-11 ZA ZA982047A patent/ZA982047B/en unknown
- 1998-03-12 BR BR9808867-0A patent/BR9808867A/en not_active Application Discontinuation
- 1998-03-12 TR TR1999/02508T patent/TR199902508T2/en unknown
- 1998-03-12 WO PCT/US1998/004735 patent/WO1998040357A2/en active IP Right Grant
- 1998-03-12 CN CNB988045389A patent/CN1179948C/en not_active Expired - Fee Related
- 1998-03-12 AU AU64575/98A patent/AU743078B2/en not_active Ceased
- 1998-03-12 AR ARP980101104A patent/AR012556A1/en active IP Right Grant
- 1998-03-12 EP EP98910300A patent/EP0970055A2/en not_active Withdrawn
- 1998-03-12 CA CA002284163A patent/CA2284163A1/en not_active Abandoned
- 1998-03-12 TW TW094100045A patent/TW200517112A/en unknown
- 1998-03-12 NZ NZ337706A patent/NZ337706A/en unknown
- 1998-03-12 JP JP53974598A patent/JP2001516350A/en not_active Ceased
- 1998-03-12 PE PE1998000171A patent/PE58799A1/en not_active Application Discontinuation
- 1998-03-12 AP APAP/P/1999/001648A patent/AP1358A/en active
- 1998-03-12 IL IL13187098A patent/IL131870A0/en active IP Right Grant
- 1998-03-12 GE GEAP19984984A patent/GEP20022764B/en unknown
- 1998-03-12 HU HU0001380A patent/HUP0001380A3/en unknown
- 1998-03-12 EE EEP199900416A patent/EE04114B1/en not_active IP Right Cessation
- 1998-03-12 SK SK1222-99A patent/SK283636B6/en not_active IP Right Cessation
- 1998-03-12 MX MXPA99008395A patent/MXPA99008395A/en not_active IP Right Cessation
- 1998-03-12 PL PL335672A patent/PL192786B1/en not_active IP Right Cessation
- 1998-03-12 EA EA199900823A patent/EA002378B1/en unknown
- 1998-03-12 MY MYPI98001071A patent/MY117535A/en unknown
- 1998-03-12 CZ CZ0319199A patent/CZ296647B6/en not_active IP Right Cessation
- 1998-03-12 KR KR10-1999-7008331A patent/KR100511089B1/en not_active IP Right Cessation
- 1998-03-13 CO CO98014251A patent/CO4940496A1/en unknown
- 1998-03-13 SV SV1998000038A patent/SV1998000038A/en not_active Application Discontinuation
- 1998-03-13 PA PA19988448801A patent/PA8448801A1/en unknown
- 1998-04-21 SA SA98181116A patent/SA98181116B1/en unknown
- 1998-12-03 UA UA99095049A patent/UA57772C2/en unknown
-
1999
- 1999-09-10 IS IS5176A patent/IS5176A/en unknown
- 1999-09-10 IL IL131870A patent/IL131870A/en not_active IP Right Cessation
- 1999-09-10 NO NO19994415A patent/NO315555B1/en not_active IP Right Cessation
- 1999-09-13 OA OA9900207A patent/OA11196A/en unknown
- 1999-09-13 BG BG103727A patent/BG63540B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY138860A (en) | Hiv protease inhibitors. | |
| DE69518840D1 (en) | N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren | |
| AP2003002915A0 (en) | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis. | |
| FI925787A0 (en) | PROTEOLYTICAL ENZYMERS SACKARINDERIVATINHIBITORER | |
| BG102048A (en) | Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors | |
| EA199800943A1 (en) | UREA DERIVATIVES AND THEIR USE AS INHIBITORS INOSINE-5`-MONO-PHOSPHATE-DEHYDROGENASE INHIBITORS | |
| ID21526A (en) | 4-HYDROXYQUINOLIN-3-CARBOXOXIDE AND HYDRAZIDE AS ANTI-VIRUS INGREDIENTS | |
| FI942423A (en) | Saccharin derivatives as inhibitors of proteolytic enzyme | |
| AU4408597A (en) | Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof | |
| ES2132383T3 (en) | PROTEASE HIV INHIBITORS. | |
| MY132553A (en) | Methods of making hiv-protease inhibitors and intermediates for making hiv-protease inhibitors | |
| BG103727A (en) | Hiv protease inhibitors | |
| TR200003797T2 (en) | New preparations derived from alpha-D-xylose, their preparation methods and uses for treatment. | |
| IT1318424B1 (en) | COMPOUNDS WITH ANTI-HIV ACTIVITY. | |
| IL129727A0 (en) | 1-(3-Aminoindazol-5-YL)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors | |
| TH14264B (en) | HIV protease inhibitors | |
| WO1998009951A3 (en) | Intermediates for making hiv-protease inhibitors and methods of making hiv-protease inhibitors |